Formulation and evaluation of cephalexin extended-release matrix tablets using hydroxy propyl methyl cellulose as rate-controlling polymer

Journal of Young Pharmacists

Volumn 4, Issue 1, 2012, Pages 3-12

  Vijay, J ^a   Sahadevan, J ^b   Prabhakaran, R ^c   Gilhotra, R ^a  

^a SURESH GYAN VIHAR UNIVERSITY   (India)

^b Grace College of Pharmacy   (India)

^c Sance Laboratories Pvt Ltd   (India)

Author keywords

Cephalexin; differential scanning calorimetry; Fourier transform infra red spectroscopic; hydroxy propyl methyl cellulose; matrix tablets; release kinetics

Indexed keywords

CEFALEXIN; HYDROXYPROPYLMETHYLCELLULOSE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COATING; DRUG IDENTIFICATION; DRUG SOLUBILITY; EXCIPIENT COMPATIBILITY; HYDROPHILICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MATRIX TABLET; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TABLET COMPRESSION; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET THICKNESS;

EID: 84858969542     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.93570     Document Type: Article

References (15)

1. Pogula M, Nazeer S. Extended release formulation. Int J Pharm Tech 2010;2:625-84.
2. Fyhr P, Downie K. Extended release drug delivery technology. Innov Pharm Tech [INTERNET] 2003. p. 80-6. Available from: http://www.iptonline. com. [Last cited on 2010 May 5].
3. Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. Vol. 1. London, Chigago: Pharmaceutical Press; c2009. p. 218-9.
4. Healthline: Connect to better health. San Fransisco, New York: Healthline Networks Inc.; 1999. Available from: http://www.healthline.com/ ahfscontent/cephalexin. [Last cited on 2011 Jan 14].
5. RxList: The Internet Drug Index. California. RxList Inc.; 1995. Available from: http://www.rxlist.com/keflex-drug.htm. [Last cited on 2011 Jan 14].
6. Shin SC, Cho SJ. Kinetics of cephalexin release from Eudragit- Hydroxypropylcellulose membranes. Drug Dev Ind Pharm 1996;22:299-305.
7. Qui Y, Chen Y, Zhang GG. Developing solid oral dosage forms: Pharmaceutical theory and practice. Burlington, USA: Elsevier Inc.; c2009. p. 125-45.
8. Moreton RC. Excipient interactions. In: Katdare A, Chaubal MV, editors. Excipient development for pharmaceutical, biotechnology, and drug delivery systems. New York: Informa Healthcare USA, Inc.; c2006. p. 101-4.
9. Niazi SK. Handbook of Preformulation. New York: Informa Healthcare USA, Inc.; c2007. p. 56, 73, 251.
10. Chang RK, Robinson JR. Sustained drug release from tablets and particles through coating Sustained release dosage form. In: Lieberman HA, Lachman L, Schwartcz JB, editors. Theory and practice of industrial pharmacy. 2nd ed. Vol. 3. New York: Marcel Dekker, Inc.; c1990. p. 200, 203-5, 235-8.
11. Shangraw RS. Compresssed tablets by direct compression. In: Lieberman HA, Lachman L, Schwartcz JB, editors. Theory and practice of industrial pharmacy. 2nd ed. Vol. 1. New York: Marcel Dekker, Inc.; c1989. p. 198-203.
12. USP 30 NF 25 2007. Rockville, MD. USA: United States Pharmacopoeial Convention Inc.; 2007. p. 1689.
13. Costa P, Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm 2001;13:123-33. (Pubitemid 32288781)
14. Grassi M, Grassi M. Mathematical modelling and controlled drug delivery: Matrix systems. Curr Drug Deliv 2005;2:97-116. (Pubitemid 40590925)
15. Yoshioka S, Stella VJ. Stability of Drugs and Dosage Forms. New York: Kluwer Academic Publishers; c2002. p. 205-13.